scholarly journals Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives

2018 ◽  
Vol 10 ◽  
pp. 175883591878031 ◽  
Author(s):  
Nuria Kotecki ◽  
Florence Lefranc ◽  
Daniel Devriendt ◽  
Ahmad Awada
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Diagnostic Techniques ◽  
Life And Death ◽  
Medical Need ◽  
Systemic Treatments ◽  
Emerging Treatments ◽  
Breast Cancer Brain Metastases

Brain metastases are the most common central nervous system tumors in adults, and incidence of brain metastases is increasing due to both improved diagnostic techniques (e.g. magnetic resonance imaging) and increased cancer patient survival through advanced systemic treatments. Outcomes of patients remain disappointing and treatment options are limited, usually involving multimodality approaches. Brain metastases represent an unmet medical need in solid tumor care, especially in breast cancer, where brain metastases are frequent and result in impaired quality of life and death. Challenges in the management of brain metastases have been highlighted in this review. Innovative research and treatment strategies, including prevention approaches and emerging systemic treatment options for brain metastases of breast cancer, are further discussed.

Current Treatment Strategies in Breast Cancer Brain Metastases

2019 ◽  
pp. 267-279
Author(s):  
Rupert Bartsch ◽  
Elisabeth Sophie Bergen ◽  
Karin Dieckmann ◽  
Anna Sophie Berghoff ◽  
Matthias Preusser
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Breast Cancer Brain Metastases

scholarly journals The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

2017 ◽  
Vol 9 (391) ◽  
pp. eaal4682 ◽  
Author(s):  
David P. Kodack ◽  
Vasileios Askoxylakis ◽  
Gino B. Ferraro ◽  
Qing Sheng ◽  
Mark Badeaux ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Treatment Strategies ◽  
Brain Lesions ◽  
Growth Delay ◽  
Luminal Breast Cancer ◽  
Pi3k Inhibition ◽  
Mechanistic Basis ◽  
Breast Cancer Brain Metastases ◽  
The Brain

Although targeted therapies are often effective systemically, they fail to adequately control brain metastases. In preclinical models of breast cancer that faithfully recapitulate the disparate clinical responses in these microenvironments, we observed that brain metastases evade phosphatidylinositide 3-kinase (PI3K) inhibition despite drug accumulation in the brain lesions. In comparison to extracranial disease, we observed increased HER3 expression and phosphorylation in brain lesions. HER3 blockade overcame the resistance ofHER2-amplified and/orPIK3CA-mutant breast cancer brain metastases to PI3K inhibitors, resulting in marked tumor growth delay and improvement in mouse survival. These data provide a mechanistic basis for therapeutic resistance in the brain microenvironment and identify translatable treatment strategies forHER2-amplified and/orPIK3CA-mutant breast cancer brain metastases.

scholarly journals Evolving treatment strategies of brain metastases from breast cancer: current status and future direction

2020 ◽  
Vol 12 ◽  
pp. 175883592093611 ◽  
Author(s):  
Jae Sik Kim ◽  
In Ah Kim
Keyword(s):  
Breast Cancer ◽  
Treatment Options ◽  
Tumor Biology ◽  
Local Treatment ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Current Status ◽  
Breast Cancer Patients ◽  
Antitumor Effects ◽  
Systemic Treatments

Remarkable progress in breast cancer treatment has improved patient survival, resulting in an increased incidence of brain metastasis (BM). Current treatment options for BM are limited and are generally used for palliative purposes. Historically, local treatment, consisting of radiotherapy and surgery, is the standard of care due to delivery limitations of systemic treatments through the blood–brain barrier. However, as novel biological mechanisms for tumors and BM have been discovered, several innovative systemic agents, such as small-molecular-targeted therapy and immunotherapy, have begun to change the treatment paradigm. In addition, efforts to maximize antitumor effects have been attempted using combination therapy, informed by tumor biology. In this comprehensive review, we will highlight various clinical trials investigating the treatment of BM in breast cancer patients, discuss presently available treatment options, and suggest potential directions of future therapeutic targets.

scholarly journals Treatment strategies for breast cancer brain metastases

2020 ◽  
Vol 124 (1) ◽  
pp. 142-155
Author(s):  
Caroline Bailleux ◽  
Lauriane Eberst ◽  
Thomas Bachelot
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Treatment Strategies ◽  
Breast Cancer Brain Metastases

CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases

2019 ◽  
Vol 144 (3) ◽  
pp. 583-589 ◽  
Author(s):  
Nicholas B. Figura ◽  
Thrisha K. Potluri ◽  
Homan Mohammadi ◽  
Daniel E. Oliver ◽  
John A. Arrington ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Hormone Receptor ◽  
Stereotactic Radiation ◽  
Hormone Receptor Positive ◽  
Breast Cancer Brain Metastases ◽  
Positive Breast Cancer

Breast cancer brain metastases: Molecular subtype, treatment and survival

2016 ◽  
Vol 36 (4) ◽  
pp. 133-141 ◽  
Author(s):  
Jennifer A. Crozier ◽  
Lauren F. Cornell ◽  
Bhupendra Rawal ◽  
Edith A. Perez
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Molecular Subtype ◽  
Breast Cancer Brain Metastases

scholarly journals MicroRNAs and Extracellular Vesicles as Distinctive Biomarkers of Precocious and Advanced Stages of Breast Cancer Brain Metastases Development

2021 ◽  
Vol 22 (10) ◽  
pp. 5214
Author(s):  
Inês Figueira ◽  
Joana Godinho-Pereira ◽  
Sofia Galego ◽  
Joana Maia ◽  
János Haskó ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endothelial Cells ◽  
Brain Metastases ◽  
Extracellular Vesicles ◽  
Triple Negative ◽  
Survival Rates ◽  
Brain Parenchyma ◽  
Advanced Stages ◽  
Breast Cancer Brain Metastases

Triple negative breast cancer presents higher mortality and poorer survival rates than other breast cancer (BC) types, due to the proneness to brain metastases formation, which are usually diagnosed at advanced stages. Therefore, the discovery of BC brain metastases (BCBM) biomarkers appears pivotal for a timely intervention. With this work, we aimed to disclose microRNAs (miRNAs) and extracellular vesicles (EVs) in the circulation as biomarkers of BCBM formation. Using a BCBM animal model, we analyzed EVs in plasma by nanoparticle tracking analysis and ascertained their blood-brain barrier (BBB) origin by flow cytometry. We further evaluated circulating miRNAs by RT-qPCR and their brain expression by in situ hybridization. In parallel, a cellular model of BCBM formation, combining triple negative BC cells and BBB endothelial cells, was used to differentiate the origin of biomarkers. Established metastases were associated with an increased content of circulating EVs, particularly of BBB origin. Interestingly, deregulated miRNAs in the circulation were observed prior to BCBM detection, and their brain origin was suggested by matching alterations in brain parenchyma. In vitro studies indicated that miR-194-5p and miR-205-5p are expressed and released by BC cells, endothelial cells and during their interaction. These results highlight miRNAs and EVs as biomarkers of BCBM in early and advanced stages, respectively.

Sign in / Sign up

Export Citation Format

Share Document